We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
Personalized mRNA vaccine showed 42% 18-month recurrence-free survival in glioblastoma. Learn details of the breakthrough JAMA study and prospects of the method.
